Abstract
The Expert Panel for Cosmetic Ingredient Safety reviewed newly available studies since their original assessment in 1982 and a previous re-review in 2002, along with updated information regarding product types and concentrations of use. Considering this information, the Panel confirmed that Laneth-9 Acetate and Laneth-10 Acetate are safe for topical application to humans in the present practices of use and concentration as described in this report.
Keywords
The Expert Panel for Cosmetic Ingredient Safety (Panel) first published the Final Report on the Safety Assessment of Laneth Acetates Group in 1982 (this report contained both Laneth-9 Acetate and Laneth-10 Acetate). 1 The Panel concluded that these ingredients are safe for topical application to humans in the present practices of use and concentration, as stated in that report. Upon re-review in 2002, the Panel reaffirmed the original conclusion, as published in 2005. 2 These 2 ingredients were originally reviewed with 3 other ingredients (Laneth-5, Laneth-16, and Laneth-25); however, these other 3 ingredients are not being reviewed herein as they have since been included in the Alkyl PEG Ethers report.
Frequency (2023/2001) and Concentration (2022/2001) of Use of Laneth-10 Acetate According to Likely Duration and Exposure and by Product Category.
NR – not reported.
aBecause each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.
bLikely duration and exposure are derived based on product category (see Use Categorization https://www.cir-safety.org/cir-findings).
cIt is possible these products are sprays, but it is not specified whether the reported uses are sprays.
dNot specified whether a spray or a powder, but it is possible the use can be as a spray or a powder; therefore, the information is captured in both categories.
In July 2023, an extensive search of the world’s literature was performed for studies dated 2000 forward, and no relevant new data were found. In summary, the Panel reviewed 2023 frequency and 2022 concentration of use data, noting the lack of use. The Panel also noted the lack of any new, available, relevant safety data. Considering this information, as well as the information provided in the original safety assessment and the prior re-review document, the Panel reaffirmed the 1982 conclusion.
Footnotes
Author Contributions
The articles in this supplement were sponsored by the Cosmetic Ingredient Review.
Author’s Note
Unpublished sources cited in this report are available from the Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review. The Cosmetic Ingredient Review is financially supported by the Personal Care Products Council.